Abstract 211P
Background
Bladder cancer belongs to one of the top ten most common cancers in the world with approximately 550,000 cases annually. The general 5-year survival rate for people with bladder cancer is 77%. The overall 10-year survival rate is 70% and the overall 15-year survival rate is 65%. Low muscle mass is prevalent in these patients receiving chemotherapy. In this meta-analysis, we aim to assess the impact of low muscle mass on overall survival in bladder cancer patients undergoing chemotherapy.
Methods
A systematic review was performed according to PRISMA guidelines. A literature search using confidence method, was conducted by two independent reviewers on all of the studies that include low muscle mass in bladder cancer patients undergoing chemotherapy using Google Scholar, PubMed, and PubMed central databases. Outcome of interest in this study is the overall survival. Data synthesis and statistical analysis were carried out using Review Manager Software.
Results
A total of 4 studies were eligible for meta-analysis including a total of 370 bladder cancer patients undergoing chemotherapy. All of the studies were observational studies. Meta-analysis revealed that there are no association between low muscle mass and overall survival (HR 1.24; 95% CI 0.71-2.19; P< 0.45). The quality of this study was assessed with Newcastle Ottawa Scale (NOS) shows “good” quality in all included studies.
Conclusions
Our meta-analysis shows that low muscle mass is not associated with the overall survival of bladder cancer patients undergoing chemotherapy. Further study need evaluate in better patient selection and adjusting the confounder.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session